DiscoverNeurology MinuteOutcomes After RCVS With Convexity Subarachnoid Hemorrhage
Outcomes After RCVS With Convexity Subarachnoid Hemorrhage

Outcomes After RCVS With Convexity Subarachnoid Hemorrhage

Update: 2025-11-20
Share

Description

Dr. Dan Ackerman and Dr. Isabel Hostettler discuss the diagnosis, risk factors, and prognosis of RCVS, highlighting the need to recognize symptoms and distinguish it from other causes of subarachnoid hemorrhage. 

Show reference: 

Hostettler IC, Ponciano A, Wilson D, et al. Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis. Neurology. 2025;105(5):e213984. doi:10.1212/WNL.0000000000213984 

Comments 
In Channel
Primary Progressive Aphasia - Part 3

Primary Progressive Aphasia - Part 3

2025-12-0101:41

Screening for Congenital Myasthenic Syndromes in Adults With Seronegative MG

Screening for Congenital Myasthenic Syndromes in Adults With Seronegative MG

2025-11-2802:11

Executive Function Deficits in Genetic Frontotemporal Dementia

Executive Function Deficits in Genetic Frontotemporal Dementia

2025-11-2701:45

Primary Progressive Aphasia - Part 2

Primary Progressive Aphasia - Part 2

2025-11-2601:23

Primary Progressive Aphasia - Part 1

Primary Progressive Aphasia - Part 1

2025-11-2502:08

Women History Minute - Sylvia Lawry

Women History Minute - Sylvia Lawry

2025-11-2405:18

Dementia with Lewy Bodies and Parkinson Disease Dementia

Dementia with Lewy Bodies and Parkinson Disease Dementia

2025-11-2102:11

Outcomes After RCVS With Convexity Subarachnoid Hemorrhage

Outcomes After RCVS With Convexity Subarachnoid Hemorrhage

2025-11-2003:32

November President Spotlight: Medicare 2026 Rulemaking

November President Spotlight: Medicare 2026 Rulemaking

2025-11-1904:09

Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)

Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)

2025-11-1803:05

Interpreting Cerebrospinal Fluid in the 2024 McDonald Criteria Revisions

Interpreting Cerebrospinal Fluid in the 2024 McDonald Criteria Revisions

2025-11-1702:27

Women History Minute - Marcelle Lapicque

Women History Minute - Marcelle Lapicque

2025-11-1404:14

Super Refractory Status Epilepticus Diagnosis, Management, and Prognostication

Super Refractory Status Epilepticus Diagnosis, Management, and Prognostication

2025-11-1304:38

Prodromal Phase of Migraine - Part 2

Prodromal Phase of Migraine - Part 2

2025-11-1202:56

Prodromal Phase of Migraine - Part 1

Prodromal Phase of Migraine - Part 1

2025-11-1103:01

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 2

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 2

2025-11-1002:16

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1

2025-11-0704:05

Neurotoxicity Imaging in Children and Young Adults After CAR T-Cell Therapy for B-Cell Malignancies

Neurotoxicity Imaging in Children and Young Adults After CAR T-Cell Therapy for B-Cell Malignancies

2025-11-0604:04

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 3

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 3

2025-11-0504:00

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 2

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 2

2025-11-0403:47

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Outcomes After RCVS With Convexity Subarachnoid Hemorrhage

Outcomes After RCVS With Convexity Subarachnoid Hemorrhage

American Academy of Neurology